SEC Form 4 · accession 0001179110-18-000392
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Narendra D. Lalwani
Officer — Chief Operating Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 3, 2018 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $66.50 | Jan 2, 2018 | A | 36,000 | A | — | Jan 2, 2028 | Common Stock | 36,000 | 36,000 | D |
Explanation of responses
- F1The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2018.